Tenax Therapeutics (TENX) 10% Owner LLC Buys $551K of Stock
Key Points
- ADAR1 Capital Management acquired 331,979 shares of Tenax Therapeutics, Inc. on October 21, 2026, boosting its total holdings to 7,447,000 shares.
- Tenax Therapeutics, Inc. trades around $1.64 per share as of October 21, 2026, up about 20.6% from its October 16 close of $1.36.
- Several Wall Street firms recently updated their outlooks on the stock, including Chardan Capital and Canaccord Genuity.
Get Tenax Therapeutics text alerts
We text you when insiders, Congress, analysts or big funds move on $TENX.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Tenax Therapeutics, Inc. alert may contain errors. Disclosures
On October 21, 2026, 10% owner ADAR1 Capital Management purchased 331,979 shares of Tenax Therapeutics, Inc. (TENX). According to a Form 4 filing with the Securities and Exchange Commission, the transaction totaled approximately $550,686.77, with shares bought at an average price of $1.66.
TENX
Tenax Therapeutics, Inc.
ADAR1 Capital Management, LLC vs. the S&P 500
Hypothetical returns from ADAR1 Capital Management, LLC's disclosed trades, not real profit or advice. How we model this.
Inside ADAR1 Capital Management's Tenax Therapeutics Trade
The purchase expanded ADAR1 Capital Management's position in the biotechnology firm by a 4.67% increase, taking its total share count to 7,447,000 shares. The trade followed several earlier purchases by the entity during the autumn.
Other Institutional Activity in Tenax Therapeutics
Other major funds have also adjusted their holdings in the drug developer. Vivo Capital, LLC grew its holdings by 2,291,667 shares, ending with 2,500,000 shares worth about $4,074,999. Perceptive Advisors Llc grew its holdings by 252,206 shares, ending with 1,700,000 shares worth about $2,770,999. Millennium Management Llc grew its holdings by 342,334 shares, ending with 876,230 shares worth about $1,428,254. Ikarian Capital, LLC reduced its holdings by 229,971 shares, ending with 787,600 shares worth about $1,283,787. Candriam S.C.A. grew its holdings by 374,794 shares, ending with 749,588 shares worth about $1,221,828.
Tenax Therapeutics, Inc. Stock Down 13.7%
Tenax Therapeutics shares recently traded around $1.64 on October 21, 2026, sitting up about 20.6% from its close of $1.36 on October 16, 2026.
Recent Earnings
Tenax Therapeutics reported an earnings per share of -$1.48 over the trailing twelve months.
Insider Buying and Selling at Tenax Therapeutics, Inc.
Insiders have been active in the stock over the prior weeks. Adar1 Capital Management LLC bought 900,000 shares on September 3, 2026, for $1,604,160. Thomas R Staab II bought 5,675 shares on September 11, 2026, for $10,981. Christopher Thomas Giordano bought 10,850 shares on September 15, 2026, for $20,087. Declan Doogan bought 53,000 shares on September 16, 2026, for $101,760.
Analysts Set New Price Targets
Wall Street firms have kept a close eye on the company's outlook. On August 11, 2026, Chardan Capital downgraded the stock with a Neutral rating and a $5.0 target. On August 11, 2026, Canaccord Genuity maintained a Buy rating with a $4.0 target. On August 11, 2026, Guggenheim maintained a Buy rating with a $4.0 target. On August 11, 2026, Evercore ISI Group downgraded the stock with an In-Line rating and a $5.0 target. Later, on August 31, 2026, Guggenheim downgraded the stock with a Neutral rating.
About Tenax Therapeutics
Tenax Therapeutics, Inc. is a development-stage pharmaceutical company based in Chapel Hill, North Carolina. It focuses on creating new cardiopulmonary treatments, including candidate therapies for pulmonary hypertension and chronic myeloid leukemia. Insider interest from major owners like ADAR1 Capital Management brings extra attention to the company's ongoing clinical development pipeline.
Bottom Line
Investors will likely monitor upcoming SEC filings and clinical updates to see how the company's pipeline progresses. The recent accumulation of shares by its largest backers highlights continued engagement with the stock.
Related Filing Alerts
Source: ADAR1 Capital Management, LLC's Form 4 filing on $TENX (Oct 21, 2026). Written by software, not financial advice. How we make alerts